Can the Competition and Markets Authority (CMA) keep up its investigation momentum? Emma Ruane discusses in The Law Society Gazette
On 15 July, the Competition and Markets Authority (CMA) found that certain pharmaceutical companies had engaged in conduct, which saw a 10,000% increase in the price of hydrocortisone tablets. Then, on 29 July, the CMA issued an infringement decision in respect of liothyronine tablets, the cost of which went up by 6,000%. These are not the first findings by regulators concerning anti-competitive behaviour by pharmaceutical companies, and they are unlikely to be the last. Yet, unless egregious wrongdoing is uncovered, it seems unlikely that the CMA will be starting any investigations into misconduct in the pharmaceutical sector in the immediate future. Read more.